Emergent BioSolutions マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Joe Papa

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	1.7yrs
取締役会の平均在任期間	3.3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Joe Papa (68 yo)

less than a year

在職期間

Mr. Joseph C. Papa, Jr. also known as Joe, is Independent Non-Executive Director of Milestone Pharmaceuticals Inc. since September 3, 2024. Mr. Papa serves as Executive Advisor at Water Street Healthcare P...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Lindahl	Executive VP	6.7yrs	US$2.18m	0.32% € 1.5m
Coleen Glessner	Executive Vice President of Global Quality and Ethics & Compliance	2.6yrs	US$1.68m	0.30% € 1.5m
Paul Williams	Senior Vice President of Products Business	1.8yrs	US$1.06m	0.045% € 219.8k
Joseph Papa	CEO, President & Director	less than a year	データなし	データなし
Jessica Perl	Senior VP	less than a year	データなし	0.013% € 61.5k
Michelle Pepin	Senior VP & Chief Human Resource Officer	1.7yrs	データなし	データなし
Stephanie Duatschek	Senior VP	1.7yrs	データなし	データなし
William Hartzel	Senior Vice President of Manufacturing & Bioservices	no data	データなし	0.088% € 428.8k
Simon Lowry	Senior VP of Research & Development and Chief Marketing Officer	no data	データなし	データなし

1.7yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: ER4の経営陣は経験豊富とはみなされません ( 1.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Joseph Papa	CEO, President & Director	less than a year	データなし	データなし
Louis Sullivan	Independent Director	18.4yrs	US$400.23k	0.099% € 482.5k
Ronald Richard	Independent Director	19.8yrs	US$394.73k	0.037% € 179.2k
Donald DeGolyer	Independent Director	1.1yrs	US$397.50k	0.027% € 131.5k
Keith Katkin	Independent Director	2.6yrs	US$396.99k	0.011% € 51.8k
Marvin White	Independent Director	4.1yrs	US$405.98k	0.068% € 331.1k
Zsolt Harsanyi	Independent Non-Executive Chairman	20.3yrs	US$535.98k	0.070% € 343.7k
Kathryn Zoon	Independent Director	8.1yrs	US$413.48k	0.068% € 334.7k
Neal Fowler	Independent Director	1.1yrs	US$398.75k	データなし
Sujata Dayal	Independent Director	2.3yrs	US$382.23k	0.0073% € 35.7k

3.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: ER4の取締役会は経験豊富であると考えられます ( 3.3年の平均在任期間)。

Emergent BioSolutions マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Independent Director recently sold €257k worth of stock

Emergent BioSolutions Inc. Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development, Effective November 18

High number of new directors

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent BioSolutions Inc. Announces Changes in CEO

Recent updates

Independent Director recently sold €257k worth of stock

Third quarter 2024 earnings released: EPS: US$2.16 (vs US$5.09 loss in 3Q 2023)

Emergent Biosolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Emergent BioSolutions Inc. Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development, Effective November 18

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc

Emergent BioSolutions Inc. to Report Q3, 2024 Results on Nov 06, 2024

Emergent BioSolutions’ ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Second quarter 2024 earnings released: US$5.38 loss per share (vs US$5.22 loss in 2Q 2023)

Emergent BioSolutions Inc. Updates Earnings Guidance for the Full Year of 2024

High number of new directors

Emergent BioSolutions Inc. to Report Q2, 2024 Results on Aug 06, 2024

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 3000 Index

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2024

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

Emergent BioSolutions Inc. to Report Q1, 2024 Results on May 01, 2024

New minor risk - Market cap size

Emergent BioSolutions Inc., Annual General Meeting, May 23, 2024

High number of new directors

Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Full year 2023 earnings released: US$14.85 loss per share (vs US$4.22 loss in FY 2022)

Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024

Emergent BioSolutions Inc. to Report Q4, 2023 Results on Mar 06, 2024

Emergent BioSolutions Inc. Announces Changes in CEO

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Emergent BioSolutions Inc. announced delayed 10-Q filing

Emergent BioSolutions Inc. Updates Earnings Guidance for the Year 2023

Emergent BioSolutions Inc. to Report Q3, 2023 Results on Nov 02, 2023

Emergent Biosolutions Inc. Announces Board Appointments

Emergent Biosolutions' Narcan®? Nasal Spray Launches over the Counter Making It Possible for Everyone to Help Save A Life from an Opioid Overdose Emergency

Emergent BioSolutions Inc. Announces Demise of Jerome Hauer, Ph.D., Director

Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

Emergent BioSolutions Inc. Announces Executive Changes

Emergent BioSolutions Inc. to Report Q2, 2023 Results on Aug 08, 2023

Emergent BioSolutions Inc. Receives U.S. FDA Approval of CYFENDUS ( Anthrax Vaccine Adsorbed, Adjuvanted), A Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Inc. Announces Resignation of Robert G. Kramer Sr. as President and Member of the Company's Board

Emergent BioSolutions Inc.(NYSE:EBS) dropped from Russell 2000 Value-Defensive Index

First quarter 2023 earnings released: US$3.65 loss per share (vs US$0.073 loss in 1Q 2022)

Emergent Biosolutions Inc. Revises Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: US$4.47 loss per share (vs US$4.32 profit in FY 2021)

Emergent BioSolutions Inc. Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

Investor sentiment improves as stock rises 17%

Emergent BioSolutions Inc. to Report Q4, 2022 Results on Feb 27, 2023

Emergent Biosolutions Inc. Announces Executive Changes

Investor sentiment improved over the past week

Emergent BioSolutions Inc. Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-The-Counter NARCAN® (Naloxone HCI) Nasal Spray

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: US$1.52 loss per share (vs US$0.61 loss in 3Q 2021)

Emergent BioSolutions Inc. Revises Earnings Guidance for the Year 2022

Now 20% undervalued after recent price drop

Emergent BioSolutions Inc. Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

Investor sentiment improved over the past week

Emergent BioSolutions Inc. to Report Q3, 2022 Results on Nov 08, 2022

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Emergent BioSolutions Inc. Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

Second quarter 2022 earnings released: US$1.13 loss per share (vs US$0.086 profit in 2Q 2021)

Emergent BioSolutions Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Investor sentiment improved over the past week

Emergent Biosolutions Announces Appointment of Sujata Dayal to Board of Directors, Member of the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight, Effective July 15, 2022

Emergent BioSolutions Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

Investor sentiment improved over the past week

Emergent BioSolutions Inc. Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

Investor sentiment improved over the past week

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings released: US$0.07 loss per share (vs US$1.31 profit in 1Q 2021)

Emergent BioSolutions Inc., Annual General Meeting, May 26, 2022

Emergent BioSolutions Inc. to Report Q1, 2022 Results on Apr 28, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Emergent BioSolutions Inc. Provides Revenue Guidance for First Quarter of 2022

マネジメント基準チェック /14